Ergoteles LLC bought a new stake in shares of Burning Rock Biotech Limited (NASDAQ:BNR – Get Rating) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 77,400 shares of the company’s stock, valued at approximately $185,000. Ergoteles LLC owned approximately 0.07% of Burning Rock Biotech at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in BNR. BlackRock Inc. raised its stake in Burning Rock Biotech by 10.8% during the 1st quarter. BlackRock Inc. now owns 1,436,749 shares of the company’s stock valued at $13,348,000 after acquiring an additional 140,533 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Burning Rock Biotech by 2.6% in the 1st quarter. Vanguard Group Inc. now owns 1,053,368 shares of the company’s stock worth $9,786,000 after buying an additional 26,289 shares in the last quarter. Invesco Ltd. raised its stake in shares of Burning Rock Biotech by 60.3% in the 1st quarter. Invesco Ltd. now owns 60,609 shares of the company’s stock worth $563,000 after buying an additional 22,805 shares in the last quarter. State Street Corp raised its stake in shares of Burning Rock Biotech by 12.9% in the 1st quarter. State Street Corp now owns 196,590 shares of the company’s stock worth $1,826,000 after buying an additional 22,457 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Burning Rock Biotech in the 1st quarter worth $97,000. Institutional investors own 22.10% of the company’s stock.
Burning Rock Biotech Stock Performance
BNR opened at $3.11 on Tuesday. Burning Rock Biotech Limited has a one year low of $1.70 and a one year high of $11.27. The stock’s fifty day moving average is $2.95 and its 200-day moving average is $2.69. The company has a market capitalization of $327.14 million, a PE ratio of -2.14 and a beta of 0.20.
Burning Rock Biotech Company Profile
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
- Get a free copy of the StockNews.com research report on Burning Rock Biotech (BNR)
- Go Where the Money Is. Here’s 3 Top Bank Dividend Stocks to Buy
- Another Catalyst For Mullen Automotive Stock
- Solar Tech-Services; Nextracker Should Be On Your Radar
- Is American Lithium a Safe Bet as Demand for Lithium Soars
- Highwoods Properties, High-quality Real Estate for a Discount
Receive News & Ratings for Burning Rock Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Burning Rock Biotech and related companies with MarketBeat.com's FREE daily email newsletter.